What is AnaptysBio, Inc.'s D&A?

AnaptysBio, Inc. (ANAB) reported D&A of $130K in Q1 2026.

How has AnaptysBio, Inc.'s D&A changed year-over-year?

AnaptysBio, Inc.'s D&A decreased by 11.0% year-over-year, from $146K to $130K.

What is the long-term trend for AnaptysBio, Inc.'s D&A?

Over 4 years (2021 to 2025), AnaptysBio, Inc.'s D&A has grown at a -2.5% compound annual growth rate (CAGR), from $619K to $559K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

AnaptysBio, Inc. ANAB D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

Eli LillyLLY

$509M+9.9%

PfizerPFE

$1.61B-0.3%

AmgenAMGN

$1.12B-19.5%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

BiogenBIIB

$204.4M+11.6%

Other financials

Income statement

See full

Revenue$25.6M-8.0%

Operating income-$34.6M-25.8%

Net income-$52.9M-34.5%

EPS (diluted)-$1.84-43.8%

Balance sheet

See full

Cash & equivalents$248.5M+152%

Total debt$13.6K-99.9%

Total equity$12.7M-62.5%

Total assets$329.7M-21.9%

Cash flow

See full

Operating cash flow-$25.9M-142%

CapEx$17.0K-51.4%

Free cash flow-$25.9M-142%

Valuation

See full

Market cap$1.73B+180%

Enterprise value$1.48B+176%

P/S7.4×+1.9×

Profitability

See full

Operating margin17.6%+9.6pp

Net margin-49.9%-22.6pp

FCF margin1.9%+1.0pp

Returns & leverage

See full

Return on equity-343.8%-1,012pp

Debt / equity0×-0.5×

Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AnaptysBio, Inc.'s D&A?: AnaptysBio, Inc. (ANAB) reported D&A of $130K in Q1 2026.
How has AnaptysBio, Inc.'s D&A changed year-over-year?: AnaptysBio, Inc.'s D&A decreased by 11.0% year-over-year, from $146K to $130K.
What is the long-term trend for AnaptysBio, Inc.'s D&A?: Over 4 years (2021 to 2025), AnaptysBio, Inc.'s D&A has grown at a -2.5% compound annual growth rate (CAGR), from $619K to $559K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.